| S1413 |
Bafilomycin A1 (Baf-A1)
|
Bafilomycin A1 (Baf-A1)是一種液泡H+-ATPase抑制劑，IC50為0.44 nM。研究發(fā)現(xiàn) Bafilomycin A1 可以抑制自噬，但是誘導(dǎo)凋亡。 |
-
Nature, 2025, 10.1038/s41586-025-09745-x
-
Cell Res, 2025, 10.1038/s41422-025-01085-9
-
Signal Transduct Target Ther, 2025, 10(1):81
|
|
| S1389 |
Omeprazole
|
Omeprazole 是一種可阻滯 H(+)-K(+)-ATPase 的質(zhì)子泵抑制劑，用于治療消化不良，消化性潰瘍，胃食管逆流，咽喉逆流。 |
-
Drug Metab Dispos, 2025, 53(4):100049
-
J Extracell Vesicles, 2024, 13(4):e12426
-
J Extracell Vesicles, 2024, 13(4):e12426
|
|
| S4845 |
Rabeprazole
|
Rabeprazole(LY307640) is an oral inhibitor of proton pump and blocks the production of acid by the stomach. |
-
J Extracell Vesicles, 2024, 13(4):e12426
-
Sci Rep, 2024, 14(1):28163
-
Med Oncol, 2024, 41(8):188
|
|
| S5658 |
Omeprazole Sodium
|
Omeprazole Sodium is the sodium salt form of omeprazole, which is a proton pump inhibitor and suppresses gastric acid secretion. Omeprazole Sodium is a metabolism-dependent inhibitor (MDI) of CYP2C19. |
-
Theranostics, 2021, 11(5):2364-2380
-
Theranostics, 2021, 11(5):2364-2380
-
J Virol, 2021, JVI.00190-21
|
|
| S2105 |
Pantoprazole
|
Pantoprazole (SKF96022, BY-1023) 是質(zhì)子泵抑制劑，抑制胃酸分泌。它作用于胃黏膜壁細(xì)胞，可逆性抑制(H+/K+)-ATPase功能以及抑制胃酸的產(chǎn)生。 |
-
Med Oncol, 2024, 41(8):188
-
Int J Mol Sci, 2022, 23-158572
-
Eur J Drug Metab Pharmacokinet, 2022, 10.1007/s13318-022-00780-x
|
|
| S1354 |
Lansoprazole
|
Lansoprazole (A-65006, AG-1749)是一種質(zhì)子泵抑制劑（PPI）可共價(jià)結(jié)合壁細(xì)胞的 H(+),K(+)-ATPase，防止胃產(chǎn)生胃酸。 |
-
Front Cell Dev Biol, 2021, 9:655559
-
J Virol, 2021, JVI.00190-21
-
Front Microbiol, 2019, 10:2790
|
|
| S4075 |
Zinc Pyrithione
|
Zinc pyrithione (OM-1563)是一種抗真菌和抗細(xì)菌藥物，可以通過阻斷質(zhì)子泵破壞膜轉(zhuǎn)運(yùn)。 |
-
Cell Chem Biol, 2021, S2451-9456(21)00213-0
-
Biol Reprod, 2019, 100(2):468-478
-
Cell Syst, 2017, 4(6-:600-610
|
|
| S4099 |
Dexlansoprazole
|
Dexlansoprazole (T 168390, TAK 390,(R)-Lansoprazole)是Lansoprazole的右旋對映體，是質(zhì)子泵抑制劑（PPI），具有雙重緩釋性能。Dexlansoprazole 作用于胃壁細(xì)胞，通過直接抑制 H(+),K(+)-ATPase 質(zhì)子泵選擇性地抑制胃酸分泌。 |
-
Food Chem Toxicol, 2025, 197:115262
-
J Immunother Cancer, 2024, 12(11)e009805
-
J Virol, 2021, JVI.00190-21
|
|
| S5608 |
Pantoprazole sodium hydrate
|
Pantoprazole (BY10232, SKF96022) sodium hydrate (Protonix) 是一種 H+/K(+)-ATPase 的有效抑制劑，其IC50值為6.8 μM。 |
-
Eur J Drug Metab Pharmacokinet, 2022, 10.1007/s13318-022-00780-x
-
J Virol, 2021, JVI.00190-21
|
|
| S4538 |
Pantoprazole sodium
|
Pantoprazole (SKF96022, BY-1023) 是質(zhì)子泵抑制劑，抑制胃酸分泌。它作用于胃黏膜壁細(xì)胞，可逆性抑制(H+/K+)-ATPase功能以及抑制胃酸的產(chǎn)生。 |
-
Eur J Drug Metab Pharmacokinet, 2022, 10.1007/s13318-022-00780-x
-
J Virol, 2021, JVI.00190-21
|
|
| S5885 |
Rabeprazole Related Compound E
|
Rabeprazole Related Compound E (Rabeprazole thioether)是rabeprazole的活性代謝物。Rabeprazole是proton pump抑制劑。 |
-
Stem Cells Int, 2022, 2022:1396735
|
|
| S5502 |
Ilaprazole sodium
|
Ilaprazole (IY-81149) sodium is the sodium salt form of ilaprazole, which is a proton pump inhibitor. Ilaprazole sodium irreversibly inhibits H(+)/K(+)-ATPase in a dose-dependent manner with IC50 of 6 μM in rabbit parietal cell preparation. |
-
J Virol, 2021, JVI.00190-21
|
|
| S3666 |
Ilaprazole
|
Ilaprazole (IY-81149)是新型的質(zhì)子泵 (proton pump)抑制劑，用于治療消化不良、消化性潰瘍、胃食管返流疾病和十二指腸潰瘍。它能抑制H+/K+-ATPase，IC50為6 μM。 |
-
bioRxiv, 2025, 2025.05.19.654850
-
Med Oncol, 2024, 41(8):188
-
J Virol, 2021, JVI.00190-21
|
|
| S4212 |
Tenatoprazole
|
Tenatoprazole (TU-199,STU-Na)是proton pump 抑制劑類前藥, 抑制質(zhì)子的運(yùn)輸，IC50為3.2 μM。Tenatoprazole 僅標(biāo)記胃部 H(+),K(+)-ATPase 的α-亞基，約2.6 nM/mg 結(jié)合于 H(+),K(+)-ATPase。
|
-
Viruses, 2024, 16(10)1566
-
J Virol, 2021, JVI.00190-21
|
|
| S4665 |
Rabeprazole sodium
|
Rabeprazole (Aciphex, Dexrabeprazole, Habeprazole)是一種抗?jié)兯幬铮?b>質(zhì)子泵的抑制劑。 |
-
J Virol, 2021, JVI.00190-21
|
|
| S5058 |
Revaprazan Hydrochloride
|
Revaprazan Hydrochloride (YH1885) 是一種新型可逆的proton pump抑制劑，具有長效抑酸活性。Revaprazan Hydrochloride 通過結(jié)合泵上K+結(jié)合位點(diǎn)來可逆性地抑制 H(+)/K(+)-ATPase。 |
-
ACS Infect Dis, 2021, 10.1021/acsinfecdis.0c00754
|
|
| S1743 |
Esomeprazole magnesium
|
Esomeprazole Magnesium(NEXIUM)通過抑制胃壁細(xì)胞中?H(+)/K(+)-ATPase (一種質(zhì)子泵(?proton pump))，減少胃酸分泌。 |
|
|
| S2222 |
PF-3716556
|
PF-3716556是一種有效的，選擇性的P-CAB鉀離子競爭性酸抑制劑，在離子滲透和離子密集檢測中，抑制豬H+，K+-ATPase活性，抑制胃酸分泌，對Na+，K+-ATPas沒有作用活性，用于治療胃食管返流疾病。 |
|
|
| E4878 |
Lansoprazole sodium
|
Lansoprazole Sodium是Lansoprazole的鈉鹽形式，是一種口服的質(zhì)子泵抑制劑，可防止胃產(chǎn)生酸。蘭索拉唑可增強(qiáng)runt相關(guān)轉(zhuǎn)錄因子2 (Runx2)的表達(dá)和轉(zhuǎn)錄效率，刺激骨祖細(xì)胞向其譜系的定向分化和成熟。 |
|
|
| E6009 |
Esomeprazole
|
Esomeprazole ((S)-Omeprazole, (-)-Omeprazole) 是一種強(qiáng)效的 質(zhì)子泵 抑制劑。它通過抑制胃壁細(xì)胞中的 H+、K+-ATPase 酶來減少酸的產(chǎn)生。Esomeprazole 的藥代動力學(xué)特性使其比 omeprazole 更有效，并有可能用于有癥狀的胃食管反流病的研究。 |
|
|
| S5847 |
Ethacrynate Sodium
|
Ethacrynate Sodium (ethacrynic acid sodium)是ethacrynic acid的鈉鹽形式。Ethacrynic acid可抑制鈉離子、鉀離子和氯離子的同鄉(xiāng)轉(zhuǎn)移，主要是在髓袢薄壁段升支，也作用于遠(yuǎn)端和近端小管。 |
|
|
| S6438 |
Ufiprazole
|
Ufiprazole (Omeprazole sulfide)是生產(chǎn)胃質(zhì)子泵抑制劑omeprazole和esomeprazole的中間物。 |
|
|
| S1413 |
Bafilomycin A1 (Baf-A1)
|
Bafilomycin A1 (Baf-A1)是一種液泡H+-ATPase抑制劑，IC50為0.44 nM。研究發(fā)現(xiàn) Bafilomycin A1 可以抑制自噬，但是誘導(dǎo)凋亡。 |
- Nature, 2025, 10.1038/s41586-025-09745-x
- Cell Res, 2025, 10.1038/s41422-025-01085-9
- Signal Transduct Target Ther, 2025, 10(1):81
|
|
| S1389 |
Omeprazole
|
Omeprazole 是一種可阻滯 H(+)-K(+)-ATPase 的質(zhì)子泵抑制劑，用于治療消化不良，消化性潰瘍，胃食管逆流，咽喉逆流。 |
- Drug Metab Dispos, 2025, 53(4):100049
- J Extracell Vesicles, 2024, 13(4):e12426
- J Extracell Vesicles, 2024, 13(4):e12426
|
|
| S4845 |
Rabeprazole
|
Rabeprazole(LY307640) is an oral inhibitor of proton pump and blocks the production of acid by the stomach. |
- J Extracell Vesicles, 2024, 13(4):e12426
- Sci Rep, 2024, 14(1):28163
- Med Oncol, 2024, 41(8):188
|
|
| S5658 |
Omeprazole Sodium
|
Omeprazole Sodium is the sodium salt form of omeprazole, which is a proton pump inhibitor and suppresses gastric acid secretion. Omeprazole Sodium is a metabolism-dependent inhibitor (MDI) of CYP2C19. |
- Theranostics, 2021, 11(5):2364-2380
- Theranostics, 2021, 11(5):2364-2380
- J Virol, 2021, JVI.00190-21
|
|
| S2105 |
Pantoprazole
|
Pantoprazole (SKF96022, BY-1023) 是質(zhì)子泵抑制劑，抑制胃酸分泌。它作用于胃黏膜壁細(xì)胞，可逆性抑制(H+/K+)-ATPase功能以及抑制胃酸的產(chǎn)生。 |
- Med Oncol, 2024, 41(8):188
- Int J Mol Sci, 2022, 23-158572
- Eur J Drug Metab Pharmacokinet, 2022, 10.1007/s13318-022-00780-x
|
|
| S1354 |
Lansoprazole
|
Lansoprazole (A-65006, AG-1749)是一種質(zhì)子泵抑制劑（PPI）可共價(jià)結(jié)合壁細(xì)胞的 H(+),K(+)-ATPase，防止胃產(chǎn)生胃酸。 |
- Front Cell Dev Biol, 2021, 9:655559
- J Virol, 2021, JVI.00190-21
- Front Microbiol, 2019, 10:2790
|
|
| S4075 |
Zinc Pyrithione
|
Zinc pyrithione (OM-1563)是一種抗真菌和抗細(xì)菌藥物，可以通過阻斷質(zhì)子泵破壞膜轉(zhuǎn)運(yùn)。 |
- Cell Chem Biol, 2021, S2451-9456(21)00213-0
- Biol Reprod, 2019, 100(2):468-478
- Cell Syst, 2017, 4(6-:600-610
|
|
| S4099 |
Dexlansoprazole
|
Dexlansoprazole (T 168390, TAK 390,(R)-Lansoprazole)是Lansoprazole的右旋對映體，是質(zhì)子泵抑制劑（PPI），具有雙重緩釋性能。Dexlansoprazole 作用于胃壁細(xì)胞，通過直接抑制 H(+),K(+)-ATPase 質(zhì)子泵選擇性地抑制胃酸分泌。 |
- Food Chem Toxicol, 2025, 197:115262
- J Immunother Cancer, 2024, 12(11)e009805
- J Virol, 2021, JVI.00190-21
|
|
| S5608 |
Pantoprazole sodium hydrate
|
Pantoprazole (BY10232, SKF96022) sodium hydrate (Protonix) 是一種 H+/K(+)-ATPase 的有效抑制劑，其IC50值為6.8 μM。 |
- Eur J Drug Metab Pharmacokinet, 2022, 10.1007/s13318-022-00780-x
- J Virol, 2021, JVI.00190-21
|
|
| S4538 |
Pantoprazole sodium
|
Pantoprazole (SKF96022, BY-1023) 是質(zhì)子泵抑制劑，抑制胃酸分泌。它作用于胃黏膜壁細(xì)胞，可逆性抑制(H+/K+)-ATPase功能以及抑制胃酸的產(chǎn)生。 |
- Eur J Drug Metab Pharmacokinet, 2022, 10.1007/s13318-022-00780-x
- J Virol, 2021, JVI.00190-21
|
|
| S5885 |
Rabeprazole Related Compound E
|
Rabeprazole Related Compound E (Rabeprazole thioether)是rabeprazole的活性代謝物。Rabeprazole是proton pump抑制劑。 |
- Stem Cells Int, 2022, 2022:1396735
|
|
| S5502 |
Ilaprazole sodium
|
Ilaprazole (IY-81149) sodium is the sodium salt form of ilaprazole, which is a proton pump inhibitor. Ilaprazole sodium irreversibly inhibits H(+)/K(+)-ATPase in a dose-dependent manner with IC50 of 6 μM in rabbit parietal cell preparation. |
- J Virol, 2021, JVI.00190-21
|
|
| S3666 |
Ilaprazole
|
Ilaprazole (IY-81149)是新型的質(zhì)子泵 (proton pump)抑制劑，用于治療消化不良、消化性潰瘍、胃食管返流疾病和十二指腸潰瘍。它能抑制H+/K+-ATPase，IC50為6 μM。 |
- bioRxiv, 2025, 2025.05.19.654850
- Med Oncol, 2024, 41(8):188
- J Virol, 2021, JVI.00190-21
|
|
| S4212 |
Tenatoprazole
|
Tenatoprazole (TU-199,STU-Na)是proton pump 抑制劑類前藥, 抑制質(zhì)子的運(yùn)輸，IC50為3.2 μM。Tenatoprazole 僅標(biāo)記胃部 H(+),K(+)-ATPase 的α-亞基，約2.6 nM/mg 結(jié)合于 H(+),K(+)-ATPase。
|
- Viruses, 2024, 16(10)1566
- J Virol, 2021, JVI.00190-21
|
|
| S4665 |
Rabeprazole sodium
|
Rabeprazole (Aciphex, Dexrabeprazole, Habeprazole)是一種抗?jié)兯幬铮?b>質(zhì)子泵的抑制劑。 |
- J Virol, 2021, JVI.00190-21
|
|
| S5058 |
Revaprazan Hydrochloride
|
Revaprazan Hydrochloride (YH1885) 是一種新型可逆的proton pump抑制劑，具有長效抑酸活性。Revaprazan Hydrochloride 通過結(jié)合泵上K+結(jié)合位點(diǎn)來可逆性地抑制 H(+)/K(+)-ATPase。 |
- ACS Infect Dis, 2021, 10.1021/acsinfecdis.0c00754
|
|
| S1743 |
Esomeprazole magnesium
|
Esomeprazole Magnesium(NEXIUM)通過抑制胃壁細(xì)胞中?H(+)/K(+)-ATPase (一種質(zhì)子泵(?proton pump))，減少胃酸分泌。 |
|
|
| S2222 |
PF-3716556
|
PF-3716556是一種有效的，選擇性的P-CAB鉀離子競爭性酸抑制劑，在離子滲透和離子密集檢測中，抑制豬H+，K+-ATPase活性，抑制胃酸分泌，對Na+，K+-ATPas沒有作用活性，用于治療胃食管返流疾病。 |
|
|
| E4878 |
Lansoprazole sodium
|
Lansoprazole Sodium是Lansoprazole的鈉鹽形式，是一種口服的質(zhì)子泵抑制劑，可防止胃產(chǎn)生酸。蘭索拉唑可增強(qiáng)runt相關(guān)轉(zhuǎn)錄因子2 (Runx2)的表達(dá)和轉(zhuǎn)錄效率，刺激骨祖細(xì)胞向其譜系的定向分化和成熟。 |
|
|
| E6009 |
Esomeprazole
|
Esomeprazole ((S)-Omeprazole, (-)-Omeprazole) 是一種強(qiáng)效的 質(zhì)子泵 抑制劑。它通過抑制胃壁細(xì)胞中的 H+、K+-ATPase 酶來減少酸的產(chǎn)生。Esomeprazole 的藥代動力學(xué)特性使其比 omeprazole 更有效，并有可能用于有癥狀的胃食管反流病的研究。 |
|
|
| S5847 |
Ethacrynate Sodium
|
Ethacrynate Sodium (ethacrynic acid sodium)是ethacrynic acid的鈉鹽形式。Ethacrynic acid可抑制鈉離子、鉀離子和氯離子的同鄉(xiāng)轉(zhuǎn)移，主要是在髓袢薄壁段升支，也作用于遠(yuǎn)端和近端小管。 |
|
|
| S6438 |
Ufiprazole
|
Ufiprazole (Omeprazole sulfide)是生產(chǎn)胃質(zhì)子泵抑制劑omeprazole和esomeprazole的中間物。 |
|
|
